Zilurgisertib (INCB000928, NBU-928) is a potent, selective and orally available wild-type and mutant ALK2 (R206H) with IC50 of 19 nM.
Zilurgisertib (INCB000928, NBU-928) has high selectivity over other BMP and TGFβ signaling receptor kinases.
INCB000928 significantly reduces the production of hepcidin in human liver cells, primary hepatocytes and rodent models of anemia.
INCB000928 has shown efficacy in preventing injury-induced heterotopic ossification in a human FOP mouse model, offering a promising path to clinical proof-of-efficacy studies and potential benefits to patients with hepcidin-induced anemia and FOP
